Canada: Sanofi's Patent For Clopidogrel (PLAVIX) Found Valid And Infringed On Appeal; Apotex's Appeal On Costs Moot (Intellectual Property Weekly Abstracts Bulletin: Week Of July 29, 2013)

Last Updated: July 31 2013
Most Read Contributor in Canada, September 2016

Edited by Chantal Saunders and Beverley Moore and Adrian Howard


Sanofi's patent for clopidogrel (PLAVIX) found valid and infringed on appeal; Apotex's appeal on costs moot

Sanofi-Aventis Inc. v. Apotex Inc.,2013 FCA 186

The Federal Court of Appeal has set aside the judgment of the Federal Court, and found that Canadian Patent No. 1,366,777 is valid, and infringed by Apotex. The matter has been sent back to the Federal Court to deal with the issue of remedies and to assess Sanofi's costs.

This is the same patent that had previously been the subject of a NOC proceeding and was appealed up to the Supreme Court of Canada, where it was found to be neither anticipated nor obvious (2008 SCC 61).

Apotex subsequently commenced an action in the Federal Court seeking a declaration that the patent was invalid. Sanofi also commenced an infringement action, and the two proceedings were consolidated into one. The Trial Judge found the patent was infringed, but invalid for lack of utility on the basis that the promise of the patent had neither been demonstrated nor soundly predicted, as well as being obvious (2011 FC 1486).

In overturning the Trial Judge, the Court of Appeal addressed the promise of the patent, obviousness and "obvious to try", and the disclosure of the factual basis for sound prediction.

The Court of Appeal clarified its earlier statements regarding the promise of the patent in Eli Lilly Canada Inc. v. Novopharm Ltd, 2010 FCA 197, stating that although the promise of the patent must be ascertained, it should not be taken to have assumed that every patent contains an explicit promise of a specific result. This is because there is no obligation on the part of the inventor to disclose the utility of his invention in the patent. If there is no explicit promise of a specific result, then a mere scintilla of utility will do.

Furthermore, patent applications are often drafted to meet world-wide requirements, and so one must be cognizant that there may be statements made that are not applicable to Canadian law. For example, European applications will often contain statements regarding industrial application, and one must be careful not to treat each reference to a practical purpose as a promise of a specific result within the meaning of Consolboard:

"Moreover, statements of or references to a specific result in a claim, which are part of the specification as expressly noted in Consolboard (such as one dealing with a new use/new utility [...]) and statements in respect of a claimed new process to make an old product to obtain a specific result [...] ought to be distinguished from expressly qualified statements as to what practical applications can be expected to flow from the demonstrated properties and advantages of a new product (such as the new compound in this case)."

For obviousness, the Court of Appeal emphasized that the genus patent described multiple compounds that did not automatically point to clopidogrel. Also, while the methods of separating a racemate into its isomers are known, it does not follow that a person skilled in the art would necessarily apply them. Lastly, the actual conduct of the inventors was helpful in determining the relative obviousness of the invention:

"Put another way, the distance between the common general knowledge and the inventive concept of the '777 Patent could not be bridged by routine experimentation since the results to be obtained were unknown. On the facts, this was confirmed by the fact that the inventors, who had more knowledge that the person of ordinary skill in the art, attempted to resolve a number of other compounds before finally trying PCR 4099."

In a concurring judgment, Gauthier JA distinguished between a situation where the invention is a new use and the situation in the present case where the invention is clopidogrel. Gauthier JA wrote that in such a case, the level of disclosure required for a sound prediction should be lower and in this case it was sufficient to state that some of the utility is based upon a prediction:

"The clear indication in the [...] patent that use in humans was predicted as opposed to demonstrated should be sufficient at law to meet the test for sound prediction. Indeed, this is enough to enable the public to know that such practical application was not demonstrated at the time the patent application was filed. Therefore, the public would have the ability to challenge the monopoly based on whether it was granted on mere speculation, and determine whether the inventor in fact had the required factual basis and sound line of reasoning to support this statement at the relevant time."

As a result of this decision in favour of Sanofi, Apotex's separate appeal on the issue of its costs was deemed to be moot (2013 FCA 187).


Architectural plans are protected by copyright and found to be infringed

Oakcraft Homes Inc v Ecklund, 2013 CanLII 41981 (ON SC)

A Small Claims decision has found that architectural drawings designed by the Plaintiff were substantially copied by the Defendants and therefore the Defendants were jointly and severally liable for the damages.

A home owner had engaged the Plaintiff to design a new home and provide drawings of their discussions. The home owner then provided those drawings to a different builder who made some changes but substantially used the drawings in building the custom home.

The Deputy Judge found that there was copyright in the drawings; copyright resided in the Plaintiff; the failure to mark the drawings as copyrighted did not defeat the claim; and, the Defendants infringed by taking a substantial part of the original.

Damages were assessed at $11,600, the mid-point of each party's positions.


Clearly Descriptive Mark Refused Registration on Appeal from Opposition Board

Continental Teves AG & Co. OHG v. Canadian Council of Professional Engineers

An appeal from a decision of a Board of the Trade-marks Opposition Board (Board) refusing the registration of ENGINEERING EXCELLENCE IS OUR HERITAGE for brake pads for land vehicles and brake rotors for land vehicles was dismissed (the Mark). The Canadian Council of Professional Engineers opposed the registration.

The Court agreed with the Board that the Mark was not shown to be distinctive. The Court also found that the Mark is clearly descriptive and therefore prohibited by section 12(1)(b) of the Trade-marks Act.

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.